中国肺癌杂志2016，Vol.19Issue(8)：515-518,4.DOI:10.3779/j.issn.1009-3419.2016.08.05
贝伐珠单抗治疗非小细胞肺癌脑转移的研究进展
Advances in Bevacizumab Therapy for Non-small Cell Lung Cancer with Brain Metastases
屈丽岩 1耿睿(综述) 1宋霞(审校)1
作者信息
- 1. 030013太原，山西医科大学附属山西省肿瘤医院呼吸科
- 折叠
摘要
Abstract
Brain metastases are frequently encountered in patients with non-small cell lung cancer (NSCLC) and are a signiifcant cause of morbidity and mortality. Antiangiogenesis therapy plays a major role in the management of brain metastases in lung cancer. Bevacizumab have become the novel method for the treatment of lung cancer with brain metastases beyond the whole brain radiation therapy, stereotactic radiosurgery and chemotherapy. Recently, more and more studies and trials laid emphasis on the bevacizumab for NSCLC with brain metastases treatment. hTe key point is the effcacy and safety. In this review, bevacizumab therapy of NSCLC with brain metastases were summarized.关键词
肺肿瘤/脑转移/贝伐珠单抗Key words
Lung neoplasms/Brain metastases/Bevacizumab引用本文复制引用
屈丽岩,耿睿(综述),宋霞(审校)..贝伐珠单抗治疗非小细胞肺癌脑转移的研究进展[J].中国肺癌杂志,2016,19(8):515-518,4.
